US panel backs trendy peptides despite safety concerns
AFPMore on this topicThe wellness industry finds its next target: New mums‘Punk wellness’: China’s stressed young people mix traditional medicine and cocktailsSee more onUnited StatesPharmaceuticals sectorUS Food and Drug Administration
- ▪AFPMore on this topicThe wellness industry finds its next target: New mums‘Punk wellness’: China’s stressed young people mix traditional medicine and cocktailsSee more onUnited StatesPharmaceuticals sectorUS Food and Drug Administration
Opening excerpt (first ~120 words) tap to expand
US panel backs trendy peptides despite safety concernsSign up now: Get ST's newsletters delivered to your inboxThe peptides are popular in wellness circles but lack strong clinical evidence. PHOTO: REUTERSPublished Jul 24, 2026, 10:40 AMUpdated Jul 24, 2026, 10:40 AMSet as preferred sourceSummariseA US panel recommended allowing specialised pharmacies to produce four trendy peptides despite safety and efficacy concerns raised by medical experts.The peptides, popular in wellness circles but lacking strong clinical evidence, include BPC-157, KPV, TB-500, and MOT-c.Critics warn the decision favours commercial interests over science and could pose risks, while supporters argue it promotes medical freedom and reduces grey market use.AI generatedNEW YORK - A US review panel on July 23…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Straits Times — World.